Henrik5000/E+ through Getty Images
- Israel based mostly computational biology firm Evogene (NASDAQ:EVGN) stated on Friday it has entered into agreements with an institutional investor for the acquisition and sale of 1.69M shares in a direct offering.
- Evogene (EVGN) expects gross proceeds of about $5.5M from the offering and intends to make use of it for working capital and normal company functions.
- The firm additionally introduced a concurrent personal placement, to concern unregistered Series A and B warrants to buy as much as 1.69M shares with an train worth of $3.55 per share.
- The closing of the direct offering is anticipated to happen on or about August twenty sixth.
- Evogene (EVGN) inventory was up 0.85% throughout buying and selling hours.
Source: Seekingalpha